Screener
Halozyme Therapeutics HALO Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $163.99M+165% | $312.01M+76.9% | $136.42M+17.8% | $419.67M+172% | $61.86M-67.1% | ||
| $453.33M+43.9% | $457.99M+50.6% | $426.27M+47.9% | $343.54M+25.8% | $315.07M+49.7% | ||
| $14.84M-53.7% | $14.84M-55.6% | $20.77M-62.4% | $29.6M-48.6% | $32.08M+2.7% | ||
| $933.02M-16.9% | $1B-20.5% | $825.21M-24.0% | $1.33B+17.9% | $1.12B+13.7% | ||
| $49.76M+25.7% | $46.93M+16.7% | $44.44M+8.8% | $40.58M+1.5% | $39.6M-1.5% | ||
| $581.73M+39.6% | $582.32M+39.7% | $580.36M+39.2% | $416.82M0.0% | $416.82M0.0% | ||
| $922.44M+190% | $951.96M+184% | $981.47M+144% | $299.84M-19.2% | $317.61M-18.3% | ||
| $2.58B+25.5% | $2.67B+21.7% | $2.53B+22.4% | $2.22B+4.9% | $2.05B+4.3% | ||
| $23.61M+26.3% | $14.1M-29.8% | $20.9M+104% | $15.36M+23.9% | $18.69M+21.1% | ||
| $4.4M— | $5.7M+613% | —— | $0-100% | $0-100% | ||
| $208.97M— | $208.74M— | $0— | $710.69M— | —— | ||
| $344.44M+157% | $363.21M+142% | $177.09M+27.3% | $837.23M+669% | $134.28M+0.7% | ||
| $1.94B+28.4% | $1.94B+28.4% | $2.14B+42.3% | $800.07M-46.8% | $1.51B+0.4% | ||
| $2.43B+41.4% | $2.45B+43.1% | $2.48B+45.7% | $1.72B+3.1% | $1.72B+2.4% | ||
| 300M0.0% | 300M0.0% | 300M+243,802% | 300M0.0% | 300M0.0% | ||
| $151.26M-58.1% | $204.84M-57.1% | $54.79M-84.8% | $502.15M+26.3% | $361.03M+38.5% | ||
| $143.54M-56.9% | $219.64M-54.5% | $48.81M-86.6% | $503.92M+11.3% | $332.75M+15.0% | ||
| $2.58B+25.5% | $2.67B+21.7% | $2.53B+22.4% | $2.22B+4.9% | $2.05B+4.3% |
FAQ
- What are Halozyme Therapeutics's total assets?
- Halozyme Therapeutics (HALO) holds $2.6B in total assets, up 25.5% year over year.
- How much debt does Halozyme Therapeutics have?
- Halozyme Therapeutics carries $2.2B in total debt against $143.5M of shareholders' equity, a debt-to-equity ratio of 15.18.
- How much cash does Halozyme Therapeutics have?
- Halozyme Therapeutics holds $164.0M in cash and equivalents.
- Can Halozyme Therapeutics cover its short-term obligations?
- Its current ratio is 2.71 — current assets exceed current liabilities.
- Where does Halozyme Therapeutics's balance sheet data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
